Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Express Scripts Expands SafeGuardRx® Program to Improve Care for Pulmonary Conditions and Multiple Sclerosis

- Pulmonary Care Value Program addresses medication adherence through remote patient monitoring, patient engagement via Express Scripts' exclusive collaboration with Mango Health, and a quality pharmacy network.

- Multiple Sclerosis Care Value Program shields payers from costs associated with discontinued therapy; leverages Accredo's specialist pharmacist support to deliver enhanced patient care and medication adherence.

Express Scripts, St. Louis, Missouri. (PRNewsFoto/Express Scripts)

News provided by

Express Scripts

Jun 01, 2017, 08:00 ET

Share this article

Share toX

Share this article

Share toX

ST. LOUIS, June 1, 2017 /PRNewswire/ -- Express Scripts (NASDAQ: ESRX) today extended its leadership in innovative, value-based care with two new Express Scripts SafeGuardRx® programs: the Pulmonary Care Value ProgramSM and the Multiple Sclerosis Care Value ProgramSM. These solutions leverage the core strengths of Express Scripts' independent model, and combine technology, specialized care and strategic industry collaborations, to deliver greater value to payers and improved health outcomes for patients living with these chronic, complex and costly illnesses.

"In these new programs, we're uniting the personalized care model in our Therapeutic Resource Centers® and Accredo® specialty pharmacy with new strategies to address the unique adherence barriers we see in patients with asthma, COPD and multiple sclerosis," said Glen Stettin, M.D., chief innovation officer, Express Scripts. "We're applying tools we've developed and tested in the Express Scripts LabSM, leveraging the success Mango Health has achieved through gamification, and collaborating with our quality pharmacy network partners to deliver improved patient outcomes."

In addition to addressing medication nonadherence, each program lowers the net cost of treatment through Express Scripts' National Preferred Formulary and utilization management programs. The Multiple Sclerosis Care Value Program also offers payers an early discontinuation reimbursement for the first three fills of a preferred multiple sclerosis (MS) medication, when filled at Accredo. Both programs will be implemented January 1, 2018.

Total medical and prescription costs for nonadherent patients are approximately $300 more per year compared to adherent patients. About 75 percent of asthma patients fail to take their medication as directed, and half of patients with asthma misuse their inhalers. The average asthma-related hospitalization costs $6,600.

Nonadherence with MS therapy increases the cost of care by $5,400 per patient annually. Additionally, more than 25 percent of MS patients discontinue therapy within the first three months because of perceived lack of efficacy, side effects and cost.

Helping Patients Breathe Easier
The Pulmonary Care Value Program (PCV) helps members who are being treated for asthma or COPD, serious conditions that place a burden on patients' quality of life and lead to dangerous and costly complications. One in 12 Americans has been diagnosed with asthma; one in 15 has been diagnosed with COPD, the third-leading cause of death in the U.S.

Express Scripts addresses the unique barriers to adherence for patients with asthma and COPD patients through these elements of the PCV program: 

  • Remote Monitoring and TRC Support: High-risk patients with asthma or COPD who are prescribed a controller inhaler will be offered remote monitoring devices to help optimize their medication use. When specialized clinicians at our Pulmonary Therapeutic Resource CenterSM (TRC), who observe the data from the monitoring devices, see that a patient is overusing their rescue inhaler or is nonadherent with their controller medication, they reach out and offer individualized care and support to get the patient back on track.
    Patients with asthma who participated in an Express Scripts Lab pilot program testing remote monitoring were breathing better during the 12-month program, as evidenced by a 60 percent to 80 percent reduction in the use of rescue inhalers, and a nearly 10 percent improvement in adherence with their asthma controller medication.
  • Patient Engagement: Our new patient engagement solution with Mango Health is a daily health platform that increases member engagement by gamifying health and rewarding patients for making healthy decisions leading to better health literacy and improved medication adherence. Through Mango's app-based approach, powered by Express Scripts' predictive data analytics and specialized care capabilities, we will deliver high-touch care to the pulmonary patients who need it most.
  • 90-day prescriptions, preferred quality retail Network: Patients can obtain a 90-day supply of medication via the Express Scripts Pharmacy or one of the 10,000 pharmacies in the preferred quality network. Research shows that 85 percent of Express Scripts patients who fill 90-day prescriptions at retail or by home delivery are adherent, compared with just 67 percent who fill 30-day prescriptions at retail.
    Similar to our Diabetes Care Value ProgramSM, pharmacies in the quality-based pharmacy network are held to a higher performance standard by Express Scripts, and are rewarded for delivering on a set of quality metrics, including high medication adherence levels.

MS: Preparing for the Pipeline 
Multiple sclerosis was the fourth-costliest drug class in 2016, with the average MS prescription costing more than $5,000. A rich drug pipeline and recently approved products are expanding treatment options for patients, including the 15 percent of patients with relapsing or primary progressive forms of MS who have not had effective treatment until 2017. These factors, along with high therapy discontinuation rates, contribute to a forecasted 10 percent increase in annual spending for the class for the next three years.

Patients with multiple sclerosis (MS) experience daily barriers and unpredictable, debilitating symptoms and depression. The high-touch care model in our Multiple Sclerosis Care Value program will help patients improve adherence and outcomes while controlling costs and medical spend. The program features:

  • Early discontinuation reimbursement: Express Scripts will reimburse payers for the first three fills of preferred multiple sclerosis medications dispensed by our Accredo specialty pharmacy if a patient discontinues the medication within the first three months.
  • Accredo's Multiple Sclerosis Therapeutic Resource CenterSM:  Accredo specialty pharmacy delivers enhanced care, helping patients achieve a market-leading adherence rate to their multiple sclerosis therapy – five percent higher compared to other pharmacies.  Specialized care at Accredo includes support such as:
    • Specialist clinician reviews for safety, effectiveness and affordability
    • Evidence-based, proprietary depression screening and counseling
    • Patient-friendly tools, including outbound phone calls, text refill reminders, and online support from the MS community

"Our independent model affords Express Scripts the flexibility to work across the industry and supply chain to develop customized solutions that address the specific barriers to cost-effective care that vary by therapy class," said Stettin. "We are leading the way with meaningful, measurable and effective value-based programs that put medicine within reach of patients."

About Express Scripts
Express Scripts puts medicine within reach of tens of millions of people by aligning with plan sponsors, taking bold action and delivering patient-centered care to make better health more affordable and accessible.

Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery pharmacy care, specialty pharmacy care, specialty benefit management, benefit-design consultation, drug utilization review, formulary management, and medical and drug data analysis services.  Express Scripts also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.

For more information, visit Lab.Express-Scripts.com or follow @ExpressScripts on Twitter.

Media Contact:
Jennifer Luddy
Express Scripts
(201) 269-6402
[email protected]

SOURCE Express Scripts

Related Links

http://www.express-scripts.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.